BPC-157 vs TB-500 – comparison of two regenerative peptides in a research context

Two peptides. Two completely different origin stories. First isolated in the 1990s from human gastric juice by a Croatian pharmacologist looking for an answer to the question of why the stomach does not digest itself. The second one was described in 1981 by an American team examining proteins of the thymus of calves and their influence on the actin cytoskeleton. BPC-157 and Thymosin Beta-4 (known commercially as TB-500) are the most frequently paired pair today regenerative peptides in research literature and in RUO supplier catalogs. Comparing them makes sense, but only if we are aware that, despite overlapping areas of activity, these are molecules with fundamentally different biology.

This article compares both peptides along five axes: origin and sequence, molecular mechanism, regenerative profile in experimental models, routes of administration and pharmacokinetics, regulatory status. The idea is to give the reader a complete picture of the differences – without implying that one peptide is “better” than the other. In specific research models, each has its place.

📖 The following article is educational and is a review of published scientific literature. Most of the cited studies were conducted on animal models or in vitro. The text does not constitute medical advice.

Origin and sequence – two different sources

BPC-157

BPC-157 (Body Protection Compound-157) was isolated in the mid-1990s by Predrag Sikiric’s team from the University of Zagreb. It comes from a fragment of a larger cytoprotective protein present in the gastric juice of mammals. Sequence:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 amino acids, M.W. 1419.53 Da)

A distinctive feature of the sequence is the presence of four proline residues (at positions 3, 4, 5 and 8), giving the peptide exceptional resistance to proteolytic hydrolysis – including gastric enzymes.

Thymosin Beta-4 (TB-500)

Thymosin Beta-4 was isolated in 1981 by Allan Goldstein and Ewald Hannappel from the thymus of calves. Full peptide sequence:

Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-T hr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser (43 amino acids)

The term “TB-500” strictly refers to the Tβ4 fragment including the LKKTETQ sequence (positions 17–23), but in RUO supplier catalogs it usually means the full peptide or a stabilized version thereof. The professional supplier clearly identifies the sequence in the COA – this is the only unambiguous identification.

Table: origin and identification

Characteristic	BPC-157	TB-500 / Thymosin Beta-4
Origin	Gastric juice of mammals	Calves’ thymus
A year of isolation	1993 (Sikiric)	1981 (Goldstein, Hannappel)
Number of amino acids	15	43 (full Tβ4) or 7 (LKKTETQ fragment)
Molecular mass	1419.53 Da	4961.4 Da (full Tβ4)
Naturally present in the body	Yes (as a fragment of a larger protein)	Yes (cytoplasmic protein)
Functional class	Cytoprotective/regenerative peptide	Beta-thymosin/cytoskeletal regulator

Molecular mechanism – fundamentally different biologies

This is the area where the differences between both peptides are most pronounced. Although the end effects are partially similar (tissue regeneration), the paths to this effect differ dramatically.

BPC-157 – Omni-directional modulator

BPC-157 does not have one single receptor. It works by modulating several parallel pathways:

Nitric oxide axis (NO/cGMP) — affects the activity of NO synthase and improves microcirculation
Angiogenic factors (VEGF, FGF) — stimulates the formation of new vessels
Growth factors (EGR-1, TGF-β, c-Met/HGF) — modulates regenerative signaling
Dopamine and serotonergic systems — affects central neurotransmission
Anti-inflammatory mechanisms — reduces TNF-α, IL-6, IL-1β

The mechanistic profile of BPC-157 is pleiotropic – the peptide “directs” the regenerative response through multiple parallel pathways, rather than by activating a single receptor.

Thymosin Beta-4 – cytoskeletal regulator

Tβ4 has one central mechanism from which all other effects arise:

G-actin sequestration — the peptide binds monomeric actin and regulates its availability for polymerization into F-actin. This is the foundation of cytoskeletal dynamics.

From this single mechanism arises a cascade of secondary effects:

Modulation of cell migration (by controlling actin polymerization in the lamellipodium)
Stimulation of angiogenesis (by influencing endothelial cell migration)
Anti-inflammatory profile (via modulation of M1/M2 macrophages)
Anti-apoptotic profile (by protecting the cytoskeleton under stress conditions)
Activation of progenitor cell precursors

Table: mechanisms

Characteristic	BPC-157	TB-500 / Thymosin Beta-4
Number of main routes	Multidirectional (5+ trails)	Central (actin sequestration)
Receptor	Missing One – Multiple Pathway Modulator	G-actin binding (not classical receptor)
Modulation of angiogenesis	Yes (via VEGF)	Yes (via endothelial cell migration)
Modulation of inflammation	Yes (pro-inflammatory cytokines)	Yes (macrophage polarization)
Effects on the nervous system	DA/5-HT modulation (brain)	No direct mechanism in the CNS
Effect on progenitor cells	Indirect (via angiogenesis)	Direct (Tβ4 reactivates epicardium)

Regenerative profile in experimental models

Both peptides are being studied in overlapping areas of regeneration, but their effectiveness in different tissue types is not identical. The table below summarizes the areas of most frequently cited activity in the literature.

Regeneration model	BPC-157	TB-500 / Tβ4
Full-wall skin wound	✓ Well documented	✓✓ Very well documented (clinical trials of RGN-137)
Stomach and gastrointestinal ulcers	✓✓ Very well documented	Poorly documented
Tendons and ligaments	✓✓ Very well documented	✓ Single works
Skeletal muscles	✓ Well documented	✓ Well documented
Myocardium (after ischemia)	✓ Single works	✓✓ Very well documented (clinical trials of RGN-352)
The cornea and epithelium of the eye	Poorly documented	✓✓ Phase III clinical trials (RGN-259)
Peripheral nerves	✓ Well documented	✓ Well documented
Bones (regeneration after fracture)	✓ Well documented	Poorly documented
Stroke/CNS ischemia	Single works	✓ Well documented

What does this table show?

Both peptides have areas where one of them has an evidentiary advantage:

BPC-157 dominates in the regeneration of the digestive tract, tendons, ligaments and bones
TB-500/Tβ4 dominates in the regeneration of the heart muscle, cornea and tissues requiring strong angiogenesis

In the areas of skin wound healing, skeletal muscle and peripheral nerve regeneration, both peptides show a similar range of activity, although through different mechanisms.

Routes of administration and pharmacokinetics

BPC-157 – Exceptional oral stability

The most distinguishing feature of the BPC-157 is its stability in the digestive tract. The peptide is resistant to hydrolysis by pepsin and acidic gastric pH – which is due to the presence of proline residues in the sequence. In experimental practice, this means that BPC-157 can be administered orally while maintaining biological activity.

Routes of administration in experiments:

Oral (unique feature among regenerative peptides)
Subcutaneous and intraperitoneal injection (most common in animal models)
Local to the area of injury

TB-500 / Tβ4 – extraoral only

Thymosin Beta-4 is not stable in the gastrointestinal tract – the peptide is broken down in the stomach. In experimental studies, only extraoral administration is used:

Subcutaneous and intraperitoneal injection
Intravenous injection (cardiac models)
Local application to the wound (with hydrogels)
Eye drops (corneal models)

In both cases, correct reconstitution of the lyophilisate is crucial – the detailed procedure is described in the guide reconstitution of peptides.

Table: pharmacokinetics

Characteristic	BPC-157	TB-500 / Thymosin Beta-4
Stability in gastric juice	High – resistance to pepsin	Low – fast hydrolysis
Possible oral route	Yes	NO
Lyophilisate stability (-20°C)	18–24 months	18–24 months
Solution stability (2-8°C)	28–30 days	14–28 days
Sensitivity to freezing cycles	Moderate	High
pH sensitivity	Low (1–9)	Moderate (preferably 6.5–7.5)

Regulatory status and sporting context

BPC-157

Registration as a medicine: none (in major jurisdictions – EMA, FDA)
RUO status: legal as a laboratory reagent in the EU and USA
WADA status: Prohibited List, category S0 – prohibited at all times
Clinical trials: limited – single pilot works, no phase III trials

TB-500 / Thymosin Beta-4

Registration as a medicine: none in major jurisdictions (despite phase II/III clinical trials of RGN-137, RGN-352, RGN-259, no preparation has achieved registration)
RUO status: legal as a laboratory reagent
WADA status: list of prohibited substances (category S2 – peptide hormones and growth factors). Athletes subject to anti-doping control cannot use the peptide at any time of the year
Clinical trials: relatively rich database – phase II and III trials for various indications, although none resulted in registration

⚠️ Professional and amateur athletes subject to doping control should absolutely avoid TB-500. BPC-157 is also on the WADA Prohibited List (category S0) and prohibited at all times.

Hypothetical synergies – what the literature says

In the regeneration research community, a question often arises about the synergy between BPC-157 and TB-500. The logic behind this hypothesis is simple: both peptides have regenerative effects, but through different mechanisms. The hypothetical combination could cover a wider range of regenerative pathways than either peptide alone.

Literature status:

There are no randomized clinical trials comparing BPC-157, TB-500, or their combination
Single animal models suggesting additive effects on tendon regeneration
Most claims of synergy come from popular literature, not from well-controlled experiments

For researchers planning experiments with both peptides: the synergy hypothesis is attractive, but requires validation in well-designed models with an appropriate control group.

Analytical specification of both peptides from the One Peptides catalog

Parameter	BPC-157	TB-500
Purity (HPLC)	≥98%	≥98%
Molecular mass (MS) identity	1419.53 Da	Compliance with the theoretical M.W.
Humidity (Karl Fischer)	≤5%	≤5%
Endotoxins (LAL)	≤1 EU/mg	≤1 EU/mg

Each vial is marked with a batch number associated with a certificate of analysis (COA). Full QC documentation is available on the website quality tests and certificates.

Which peptide for which experiment

A practical summary for researchers:

Purpose of the experiment	A better choice
Models of gastric ulcers, IBD	BPC-157
Achilles tendon injury models	BPC-157
Knee ligament injury models	BPC-157
Models of bone regeneration	BPC-157
Models of myocardial ischemia	TB-500 / Tβ4
Corneal injury models	TB-500 / Tβ4
Diabetic wound models	Both, with a preference for Tβ4
Models of CNS ischemic stroke	TB-500 / Tβ4
Models of peripheral neuropathy	Both
Models of muscular dystrophy	TB-500 / Tβ4
Experiments requiring oral administration	BPC-157 (only option)

FAQ – Frequently asked questions

Which peptide is “better” – BPC-157 or TB-500?

The question has no clear answer. Each of the peptides has areas where it shows evidence superiority. BPC-157 dominates the regeneration of the digestive tract, tendons and bones and is the only one that can be administered orally. TB-500/Tβ4 dominates the regeneration of the heart muscle, cornea and tissues requiring strong angiogenesis. The choice depends on the specific research model.

Can both peptides be combined in an experiment?

The synergy hypothesis is popular in the regeneration research community, but there is a lack of randomized clinical trials confirming the additivity of the effects. Single animal models suggest positive results, but the data are not yet sufficient to draw firm conclusions.

Do BPC-157 and TB-500 have the same WADA status?

NO. TB-500 / Thymosin Beta-4 is on the WADA Prohibited Substances List (Category S2). BPC-157 is on the WADA Prohibited List, category S0. Athletes subject to anti-doping control cannot use TB-500 at any time of the year, the status of BPC-157 requires regular verification.

Why can BPC-157 be administered orally but TB-500 cannot?

The difference is due to the amino acid structure. BPC-157 contains four proline residues in the sequence (positions 3, 4, 5, 8) that block cleavage by gastric enzymes (pepsin). TB-500/Tβ4 does not have this type of structural protection – the peptide is rapidly hydrolyzed in gastric juice before reaching the bloodstream.

Which peptide has more evidence from human studies?

TB-500 / Thymosin Beta-4 has a relatively extensive database of clinical trials (RGN-137, RGN-352, RGN-259 from RegeneRx Biopharmaceuticals), although none have resulted in registration as a drug in major jurisdictions. BPC-157 has a much more modest clinical base – single pilot studies on small groups of patients, mainly with gastrointestinal diseases.

Are any of the peptides registered as a medicine in the European Union?

NO. Neither BPC-157 nor TB-500/Thymosin Beta-4 are registered as medicines by the EMA. Both remain research peptides (Research Use Only).

How does the solution stability of both peptides differ?

BPC-157 is a relatively stable peptide – after reconstitution in bacteriostatic water, it remains active for 28-30 days in a refrigerator at 2-8°C. TB-500 / Tβ4 is less stable – typical solution stability is 14-28 days under the same conditions. Freeze/thaw cycles should be avoided with both peptides.

Bibliography

Sikiric P, Hahm KB, Blagaic AB, et al. (2020). Stable gastric pentadecapeptide BPC 157, Robert’s stomach cytoprotection/adaptive cytoprotection/organoprotection, and Selye’s stress coping response
Goldstein AL, Hannappel E, Sosne G, Kleinman HK (2012). Thymosin β4: a multi-functional regenerative peptide
Chang CH, Tsai WC, Hsu YH, Pang JS (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts
Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004). Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair
Hsieh MJ, Liu HT, Wang CN, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Malinda KM, Sidhu GS, Mani H, et al. (1999). Thymosin beta4 accelerates wound healing
Cerovecki T, Bojanic I, Brcic L, et al. (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
Sosne G, Qiu P, Goldstein AL, Wheater M (2010). Biological activities of thymosin β4 defined by active sites in short peptide sequences
Smart N, Risebro CA, Melville AAD, et al. (2006). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization
Crockford D, Turjman N, Allan C, Angel J (2010). Thymosin β4: structure, function, and biological properties supporting current and future clinical applications
World Anti-Doping Agency (2024). The 2024 prohibited list — international standard

Global disclaimer

All One-Peptides products are reagents intended exclusively for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for human consumption. The information in this article is educational in nature and is a review of published scientific literature; does not constitute medical, pharmaceutical or dietary advice. Thymosin Beta-4 is on the WADA prohibited substances list – athletes subject to anti-doping control cannot use the peptide. The status of BPC-157 (WADA Monitoring List) requires regular review.

Pharmaceutical review: MPharm Aneta Kropicka
Pharmaceutical reviewer and sports supplementation expert.
Master of Pharmacy with 12 years of professional experience, graduate of the Medical University of Łódź (2014). Verifies One Peptides content for pharmacology, clinical dosing, and regulatory compliance across RUO / dietary supplement / drug frameworks.

Published: 2026-05-29 • Last updated: 2026-06-03

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›